Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan
  
Leaves_Lungs
Sanofi's itepekimab fails to dazzle in COPD • Source: Shutterstock

More from Strategy

More from Therapy Areas